<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750709</url>
  </required_header>
  <id_info>
    <org_study_id>CT-001</org_study_id>
    <secondary_id>PXL225418</secondary_id>
    <nct_id>NCT02750709</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin</brief_title>
  <official_title>A Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 Healthy Male and Female Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cycle Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cycle Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product 1&#xD;
      (TP1)) and Nitisinone 10 mg Tablets High Compritol (Test Product 2 (TP2)) are bioequivalent&#xD;
      to the reference product Orfadin 10 mg capsules.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim is to conduct a randomized, single dose, three-period cross-over&#xD;
      bioequivalence (BE) study in at least 18 healthy male and female subjects at a single study&#xD;
      center to evaluate the in vivo performance of Nitisinone 10 mg Tablet (Test Product 1) and&#xD;
      Nitisinone 10 mg Tablet High Compritol (Test Product 2) to the reference product Orfadin 10&#xD;
      mg capsules.&#xD;
&#xD;
      The pharmacokinetics (PK) of Test Product 1 and 2 compared to the reference product, will be&#xD;
      determined and compared in healthy volunteers.&#xD;
&#xD;
      The modified version of Nitisinone Tablet (Test Product 2, higher glyceryl dibehenate&#xD;
      (Compritol 888)) was administered to determine the acceptance limit of the dissolution&#xD;
      profile for Nitisinone tablets with a longer dissolution time (Test Product 2) since the&#xD;
      dissolution time of Nitisinone tablets (Test Product 1) lengthened over time under&#xD;
      accelerated study conditions. The hypothesis is that should bioequivalence between Test&#xD;
      Product 1 and Test Product 2 be demonstrated then it is concluded that the prolonged&#xD;
      dissolution time had no impact on the bioequivalence of Nitisinone tablets.&#xD;
&#xD;
      A total of 24 healthy female and male volunteers (age 18 to 55 years old) will be entered&#xD;
      into the study. Volunteers will be determined to be free of significant medical conditions as&#xD;
      assessed by medical history, physical examination, and blood and urine tests. Volunteers will&#xD;
      be randomly allocated to receive one of the three treatment sequence groups and, on each&#xD;
      occasion, receive one of the following: Nitisinone 10 mg Tablet, Nitisinone 10 mg High&#xD;
      Compritol Tablet and Orfadin 10 mg hard capsules (reference listed drug, (RLD)). There will&#xD;
      be a minimum 23 calendar days washout between treatments. Blood samples will be collected at&#xD;
      pre-dose (0 hours) and at 15 minutes, 30 minutes, 1 hour, 2 hours, 2 hours and 30 minutes, 3&#xD;
      hours, 3 hours and 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 10 hours, 12&#xD;
      hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours post-dose (total: 21&#xD;
      samples per treatment period).&#xD;
&#xD;
      The primary endpoints will be the maximum blood concentration (Cmax) and the area under the&#xD;
      curve (AUC) from time zero to 120 hours post-dose.&#xD;
&#xD;
      For the FDA, bioequivalence of the test and reference products will be assessed on the basis&#xD;
      of the 90% confidence intervals for estimates of the geometric mean ratios between the&#xD;
      primary PK parameters of the test and reference products using an analysis of variance&#xD;
      considering the bioequivalence range of 80.00% to 125.00% for Cmax and AUC(0-120).&#xD;
&#xD;
      For Health Canada, bioequivalence of the test and reference products will be assessed on the&#xD;
      basis of the 90% confidence interval for estimate of the geometric mean ratio between the&#xD;
      primary PK parameter AUC(0-120) of the test and reference products using an analysis of&#xD;
      variance considering the bioequivalence range of 80.00% to 125.00% and the point estimate of&#xD;
      the geometric mean ratio of the primary PK parameter Cmax considering the bioequivalence&#xD;
      range of 80.00% to 125.00%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (λz)</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2)</measure>
    <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hereditary Tyrosinemia, Type I</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.</description>
    <arm_group_label>Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone 10 mg Tablet High Compritol</intervention_name>
    <description>A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.</description>
    <arm_group_label>Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orfadin</intervention_name>
    <description>A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
    <arm_group_label>Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)</arm_group_label>
    <arm_group_label>Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)</arm_group_label>
    <arm_group_label>Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 30 kg/m2 (inclusive).&#xD;
&#xD;
          -  Body mass not less than 50 kg.&#xD;
&#xD;
          -  Medical history, vital signs, physical examination, standard 12-lead electrocardiogram&#xD;
             (ECG) and laboratory investigations must be clinically acceptable or within laboratory&#xD;
             reference ranges for the relevant laboratory tests, unless the investigator considers&#xD;
             the deviation to be irrelevant for the purpose of the study.&#xD;
&#xD;
          -  Non-smokers.&#xD;
&#xD;
          -  Females, if:&#xD;
&#xD;
        Not of childbearing potential, e.g., has been surgically sterilized, undergone a&#xD;
        hysterectomy, amenorrhea for ≥ 12 months and considered post-menopausal,&#xD;
&#xD;
        Note: In postmenopausal women, the value of the serum pregnancy test may be slightly&#xD;
        increased. This test will be repeated to confirm the results. If there is no increase&#xD;
        indicative of pregnancy, the female will be included in the study.&#xD;
&#xD;
        OR&#xD;
&#xD;
        Of childbearing potential, the following conditions are to be met:&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  If this test is positive, the subject will be excluded from the study. In the rare&#xD;
             circumstance that a pregnancy is discovered after the subject received Investigational&#xD;
             Medicinal Product (IMP), every attempt must be made to follow her to term.&#xD;
&#xD;
          -  Not lactating&#xD;
&#xD;
          -  Abstaining from sexual activity (if this is the usual lifestyle of the subject) or&#xD;
             must agree to use an accepted method of contraception, and agree to continue with the&#xD;
             same method throughout the study&#xD;
&#xD;
        Examples of reliable methods of contraception include non-hormonal intrauterine device, and&#xD;
        barrier methods combined with an additional contraceptive method.&#xD;
&#xD;
        In this study the concomitant use of hormonal contraceptives is NOT allowed.&#xD;
&#xD;
        Other methods, if considered by the investigator as reliable, will be accepted.&#xD;
&#xD;
          -  Written consent given for participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional&#xD;
             or intellectual problems likely to limit the validity of consent to participate in the&#xD;
             study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          -  Current alcohol use &gt; 21 units of alcohol per week for males and &gt; 14 units of alcohol&#xD;
             per week for females.&#xD;
&#xD;
          -  Consumption of more than 5 cups of coffee (or equivalent amounts of caffeine) per day.&#xD;
&#xD;
          -  Regular exposure to substances of abuse (other than alcohol) within the past year.&#xD;
&#xD;
          -  Use of any medication, prescribed or over-the-counter or herbal remedies, within 2&#xD;
             weeks before the first administration of IMP except if this will not affect the&#xD;
             outcome of the study in the opinion of the investigator. In this study the concomitant&#xD;
             use of hormonal contraceptives is NOT allowed.&#xD;
&#xD;
          -  Participation in another study with an experimental drug, where the last&#xD;
             administration of the previous IMP was within 8 weeks (or within 10 elimination&#xD;
             half-lives for chemical entities or 2 elimination half-lives for antibodies or&#xD;
             insulin), whichever is the longer) before administration of IMP in this study, at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  Treatment within the previous 3 months before the first administration of IMP with any&#xD;
             drug with a well-defined potential for adversely affecting a major organ or system.&#xD;
&#xD;
          -  A major illness during the 3 months before commencement of the screening period.&#xD;
&#xD;
          -  History of hypersensitivity or allergy to the IMP or its excipients or any related&#xD;
             medication.&#xD;
&#xD;
          -  History of bronchial asthma or any other bronchospastic disease.&#xD;
&#xD;
          -  History of convulsions.&#xD;
&#xD;
          -  History of porphyria.&#xD;
&#xD;
          -  Relevant history or laboratory or clinical findings indicative of acute or chronic&#xD;
             disease, likely to influence study outcome.&#xD;
&#xD;
          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the&#xD;
             first administration of IMP.&#xD;
&#xD;
          -  Diagnosis of hypotension made during the screening period.&#xD;
&#xD;
          -  Diagnosis of hypertension made during the screening period or current diagnosis of&#xD;
             hypertension.&#xD;
&#xD;
          -  Resting pulse of &gt; 100 beats per minute or &lt; 40 beats per minute during the screening&#xD;
             period, either supine or standing.&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), Hepatitis B and Hepatitis C.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse. In case of a positive result the urine&#xD;
             screen for drugs of abuse may be repeated once at the discretion of the investigator.&#xD;
&#xD;
          -  Positive urine screen for tobacco use.&#xD;
&#xD;
          -  Positive pregnancy test.&#xD;
&#xD;
          -  Female subjects that are pregnant or breastfeeding.&#xD;
&#xD;
          -  Difficulty in swallowing.&#xD;
&#xD;
          -  Any specific investigational product safety concern.&#xD;
&#xD;
          -  Vulnerable subjects, e.g. persons in detention.&#xD;
&#xD;
          -  Subjects with current keratopathy, or other clinically significant abnormalities found&#xD;
             by slit-lamp examination (cataracts) at the discretion of the investigator.&#xD;
&#xD;
          -  Concomitant use of medications that are metabolized by CYP2C9 (ibuprofen, diclofenac&#xD;
             and indomethacin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Nell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloemfontein Early Phase Clinical Unit, PAREXEL Internation (South Africa)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HT-1</keyword>
  <keyword>Tyrosinemia</keyword>
  <keyword>Nitisinone</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Orfadin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tyrosinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)</title>
          <description>Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)</title>
          <description>Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)</title>
          <description>Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.&#xD;
Nitisinone: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.&#xD;
Nitisinone 10 mg Tablet High Compritol: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.&#xD;
Orfadin: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1137.40" spread="17.9"/>
                    <measurement group_id="O2" value="1080.69" spread="24.2"/>
                    <measurement group_id="O3" value="1168.71" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66220.91" spread="19.0"/>
                    <measurement group_id="O2" value="61883.52" spread="23.1"/>
                    <measurement group_id="O3" value="66199.76" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49448.49" spread="19.8"/>
                    <measurement group_id="O2" value="46401.12" spread="37.6"/>
                    <measurement group_id="O3" value="49582.69" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91226.27" spread="26.6"/>
                    <measurement group_id="O2" value="83245.33" spread="37.0"/>
                    <measurement group_id="O3" value="89394.35" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="7.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="0.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (λz)</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>1/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="29.1"/>
                    <measurement group_id="O2" value="0.012" spread="20.6"/>
                    <measurement group_id="O3" value="0.012" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2)</title>
        <time_frame>0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours</time_frame>
        <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Nitisinone Tablet, 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Nitisinone Tablet (High Compritol), 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Reference Product</title>
            <description>ORFADIN® hard capsule, 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2)</title>
          <population>All subjects for whom the primary PK parameters Cmax and AUC(0-120) could be calculated for at least 2 treatment periods (where one of the treatment periods is the Reference product), and who had no major protocol deviations thought to impact on the analysis of the PK data were included in the statistical PK analysis for the study.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.42" spread="29.1"/>
                    <measurement group_id="O2" value="58.41" spread="20.6"/>
                    <measurement group_id="O3" value="59.43" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the period of the study (December 2015 - January 2016).</time_frame>
      <desc>24 subjects were entered in to the study and randomly assigned to treatment sequence according to randomization schedule before first administration of the Investigational Medicinal Product (IMP). One subject was withdrawn from the study after Treatment Period 1 (Reference Product) because they vomited within 2 times median Tmax. As a result, 24 subjects completed dosing of Reference Product and 23 subjects completed the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Product 1</title>
          <description>Nitisinone Tablet, 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Test Product 2</title>
          <description>Nitisinone Tablet (High Compritol), 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Reference Product</title>
          <description>ORFADIN® hard capsule, 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaso Vagal Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching Fingers</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Price</name_or_title>
      <organization>Cycle Pharmaceuticals Ltd</organization>
      <phone>+44 1223 803638</phone>
      <email>james.price@cyclepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

